Cydan Raises $34M to Advance New Therapies for Sickle Cell, Other Rare Diseases | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Cydan Raises $34M to Advance New Therapies for Sickle Cell, Other Rare Diseases


Cydan, the company that founded Imara — which developed a sickle cell disease (SCD) treatment candidate, IMR-687 — has raised $34 million in new financing to advance innovative therapies for patients living with SCD and other rare diseases.

Cydan, based in Cambridge, Massachusetts, identifies promising scientific findings and drug candidates and advances them into clinical development. Cydan also establishes independent companies to promote selected therapies through clinical development and regulatory approval. In this round of financing, a new investor, Longitude Capital, joined existing investors New Enterprise Associates (NEA), Pfizer Venture Investments, Alexandria Venture Investments and Lundbeckfond Ventures.

https://www.onescdvoice.com/wp-content/uploads/2017/11/Cydan-Raises.jpg